CKD Bio Corp. (KRX:063160)
South Korea · Delayed Price · Currency is KRW 14,100
+200 (1.44%)
Sep 1, 2026, 3:30 PM KST
CKD Bio Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
| 76,255 | 130,566 | 229,313 | 438,328 | 158,885 | 106,437 | |
Market Cap Growth | -39.30% | -43.06% | -47.69% | 175.88% | 49.28% | 68.02% |
Enterprise Value | - | 251,285 | 333,496 | 515,471 | 171,618 | 114,125 |
Last Close Price | 13900.00 | 23691.32 | 41609.13 | 79343.05 | 29214.98 | 19440.71 |
Price Ratios
Fiscal Year | Current | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
PE Ratio | - | - | - | 70.61 | 12.95 | 13.38 |
Forward PE | - | 20.10 | 20.10 | 30.19 | 10.95 | - |
PS Ratio | 0.48 | 0.84 | 1.61 | 3.52 | 1.16 | 0.86 |
PB Ratio | 0.58 | 0.88 | 1.42 | 2.60 | 1.00 | 0.72 |
P/TBV Ratio | 0.61 | 0.91 | 1.45 | 2.64 | 1.01 | 0.73 |
P/OCF Ratio | - | - | - | 90.86 | 9.35 | 6.85 |
EV Ratios
Fiscal Year | Current | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
EV/Sales Ratio | - | 1.61 | 2.35 | 4.14 | 1.25 | 0.92 |
EV/EBITDA Ratio | - | 80.34 | 60.07 | 25.98 | 6.81 | 7.15 |
EV/EBIT Ratio | - | - | - | 67.76 | 11.14 | 16.28 |
Financial Efficiency
Fiscal Year | Current | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
Debt / Equity Ratio | 1.21 | 0.94 | 0.68 | 0.47 | 0.18 | 0.03 |
Debt / EBITDA Ratio | - | 44.41 | 19.70 | 4.02 | 1.13 | 0.31 |
Net Debt / Equity Ratio | 1.12 | 0.85 | 0.66 | 0.46 | 0.15 | -0.08 |
Net Debt / EBITDA Ratio | -19.84 | 40.35 | 19.06 | 3.95 | 0.95 | -0.74 |
Net Debt / FCF Ratio | -6.43 | -13.42 | -4.01 | -1.38 | -0.78 | 13.82 |
Asset Turnover | 0.51 | 0.51 | 0.49 | 0.48 | 0.66 | - |
Inventory Turnover | 2.04 | 1.87 | 1.99 | 2.14 | 3.38 | - |
Quick Ratio | 0.65 | 0.49 | 0.76 | 0.58 | 1.06 | 2.03 |
Current Ratio | 1.56 | 1.51 | 2.36 | 1.92 | 1.78 | 3.31 |
Return on Equity (ROE) | -16.26% | -10.80% | -3.98% | 3.79% | 8.01% | - |
Return on Assets (ROA) | -4.96% | -3.03% | -2.46% | 1.84% | 4.61% | - |
Return on Invested Capital (ROIC) | -9.07% | -5.47% | -4.45% | 3.12% | 7.60% | 4.42% |
Return on Capital Employed (ROCE) | -10.80% | -6.40% | -4.50% | 3.20% | 8.20% | 4.40% |
Yields
Fiscal Year | Current | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
Earnings Yield | -30.33% | -12.79% | -2.87% | 1.42% | 7.72% | 7.47% |
FCF Yield | -29.94% | -7.20% | -11.50% | -12.97% | -19.09% | -0.81% |
Dividend Yield | - | - | 0.24% | 0.25% | 0.65% | 0.98% |
Payout Ratio | - | - | - | 16.53% | 8.36% | 25.79% |
Buyback Yield / Dilution | 0.02% | - | -1.40% | -0.46% | 0.00% | 0.03% |
Total Shareholder Return | 0.02% | - | -1.16% | -0.20% | 0.65% | 1.01% |